Last updated: August 29, 2026
Myleran is the oral formulation of busulfan, an alkylating chemotherapy agent historically used primarily for chronic myeloid leukemia and other myeloproliferative disorders. Its commercial value has declined sharply because the product is old, generic competition is established, chronic myeloid leukemia treatment has shifted toward targeted kinase inhibitors, and intravenous busulfan products have captured the main transplant-conditioning opportunity. Myleran has no meaningful current patent-based pricing power, and standalone revenue is not publicly disclosed.
What is Myleran and how is busulfan used?
Myleran contains busulfan, a bifunctional alkylating agent that cross-links DNA and suppresses bone-marrow activity. The oral tablets were historically marketed for chronic myeloid leukemia and related hematologic conditions. Busulfan is also used in conditioning regimens before hematopoietic stem-cell transplantation, although that market is primarily served by intravenous products.
| Attribute |
Myleran |
| Active ingredient |
Busulfan |
| Dosage form |
Oral tablet |
| Therapeutic class |
Alkylating antineoplastic |
| Historical primary use |
Chronic myeloid leukemia |
| Current transplant relevance |
Limited for oral Myleran; intravenous busulfan is preferred |
| Original developer/brand lineage |
Burroughs Wellcome, later associated with GlaxoSmithKline |
| U.S. commercial position |
Legacy product with limited strategic importance |
| Patent position |
Core composition and early product rights expired decades ago |
| Current competitive basis |
Generic availability, supply reliability, clinical familiarity, and hospital procurement |
The Myleran label reflects its historical role in chronic myeloid leukemia rather than the current standard of care for that disease. The National Cancer Institute identifies tyrosine kinase inhibitors, including imatinib, dasatinib, nilotinib, bosutinib, and ponatinib, as central treatments for Philadelphia chromosome-positive chronic myeloid leukemia. This has structurally reduced demand for long-term busulfan therapy.[1]
When did Myleran lose exclusivity?
Myleran lost meaningful exclusivity long before the modern pharmaceutical patent era. The original busulfan patents and associated regulatory protections expired many years ago. The product therefore has no remaining composition-of-matter exclusivity or commercially significant original formulation exclusivity.
What is the Orange Book status of Myleran?
The U.S. Food and Drug Administration’s Orange Book is the primary source for current listed patents and exclusivity associated with approved small-molecule products. Myleran does not have a commercially relevant active patent estate comparable with newer oncology products. Any current commercial protection would depend on manufacturing know-how, supply contracts, trademarks, or regulatory execution rather than enforceable patent exclusivity.[2]
The absence of active core patents has several consequences:
- Generic manufacturers can compete on price.
- Paragraph IV litigation is unlikely to be commercially significant for the original Myleran product.
- No meaningful patent cliff remains because the cliff occurred decades ago.
- Market share depends on availability and procurement rather than exclusivity.
- A new busulfan formulation would need separate patentable technical features to obtain protection.
How has the Myleran market changed?
Myleran’s market has contracted through three successive changes in treatment practice.
Chronic myeloid leukemia moved to targeted therapy
Busulfan was historically used for cytoreduction in chronic myeloid leukemia. The introduction of BCR-ABL tyrosine kinase inhibitors changed treatment economics and clinical practice. Imatinib and later-generation kinase inhibitors offer disease control through a targeted mechanism and have become the principal therapy for most patients with Philadelphia chromosome-positive disease.[1]
This transition reduced the addressable population for chronic oral busulfan. Myleran remains relevant only in narrow clinical circumstances, including selected patients who cannot receive or do not respond adequately to preferred targeted therapies.
Transplant use moved toward intravenous busulfan
Busulfan remains relevant in hematopoietic stem-cell transplantation, but intravenous administration provides more predictable exposure than oral dosing. Oral busulfan has variable absorption and requires careful dose management. Intravenous busulfan products permit pharmacokinetic monitoring and are incorporated into conditioning regimens with cyclophosphamide, fludarabine, or other agents.
The commercial value of busulfan therefore shifted from the oral Myleran product to intravenous formulations such as Busulfex and generic injectable busulfan. The active ingredient remains clinically important, but that importance does not translate into equivalent demand for Myleran tablets.
Generic competition compressed price
Busulfan is a mature small molecule with no meaningful patent barrier. Generic oral and injectable products can compete through abbreviated new drug applications rather than full clinical development programs. Hospitals and transplant centers commonly evaluate these products through formulary, purchasing, supply continuity, and pharmacokinetic considerations.
The result is a low-growth market with price pressure. Any increase in oncology or transplant volume is unlikely to produce material revenue growth for the original Myleran brand.
What is the financial trajectory of Myleran?
Myleran’s financial trajectory is best characterized as long-term erosion followed by niche stabilization. The product is not generally reported as a standalone revenue line by its historical corporate owners, so a reliable public figure for annual Myleran sales is not available. Corporate filings typically aggregate mature oncology products, regional brands, or discontinued and noncore assets.
| Period |
Commercial trajectory |
Main driver |
| Pre-2000 |
Established oral chemotherapy product |
Limited alternatives for chronic myeloid leukemia |
| 2000s |
Decline in leukemia use |
Adoption of imatinib and other kinase inhibitors |
| 2000s-2010s |
Shift in busulfan value toward IV products |
Transplant conditioning favored controlled exposure |
| 2010s-2020s |
Generic price pressure |
Loss of exclusivity and multiple suppliers |
| Current market |
Low-value legacy niche |
Residual demand, procurement, and supply continuity |
The most important financial distinction is between the busulfan market and Myleran revenue. Busulfan retains clinical demand in transplant conditioning, but much of that demand is attached to intravenous products rather than oral Myleran. A market report showing growth in busulfan sales may therefore overstate the commercial outlook for Myleran tablets.
Which companies challenge Myleran?
Competition comes from two groups: oral busulfan suppliers and intravenous busulfan manufacturers.
Oral busulfan competition
Oral busulfan competitors can offer the same active ingredient without reproducing the original brand’s historical development costs. Their commercial advantages include lower pricing and procurement flexibility. Their disadvantages can include limited distribution, intermittent supply, and lower physician familiarity.
Intravenous busulfan competition
The more important competitive products are intravenous busulfan products used in transplantation. Busulfex was developed as an intravenous formulation for conditioning before hematopoietic progenitor-cell transplantation. Generic injectable busulfan products subsequently expanded access and increased price competition.
Intravenous products compete on:
- Pharmacokinetic monitoring capability
- Hospital formulary placement
- Manufacturing reliability
- Shortage performance
- Contracting terms
- Transplant-center experience
- Regulatory compliance
This competition affects the overall busulfan market but does not directly create a growth path for oral Myleran.
What patent and regulatory barriers protect busulfan products?
Formulation patents
The original oral Myleran formulation has no commercially meaningful remaining formulation exclusivity. A newer oral or intravenous busulfan product could seek patent protection for:
- Improved solubility or stability
- Reduced dosing variability
- Modified-release delivery
- Lower-toxicity formulations
- Novel excipients
- Pharmacokinetic control
- Combination regimens
- Device-assisted administration
Such patents would protect the new formulation, not the historical Myleran product.
Method-of-use patents
Potential method-of-use claims could cover busulfan in specific conditioning regimens, patient populations, dosing schedules, or pharmacokinetic targets. Their commercial value would be limited by the age of the molecule, extensive prior art, and the ability of competitors to design around narrow treatment claims.
Manufacturing and supply barriers
Manufacturing remains more important than patent protection. Busulfan is a potent cytotoxic compound that requires controlled handling, validated analytical methods, specialized containment, and regulatory-compliant production. These factors can discourage casual market entry, but they do not create durable monopoly pricing.
The principal barriers are:
- Cytotoxic compound handling
- Validated impurity controls
- Batch consistency
- Stability and packaging requirements
- Regulatory inspection readiness
- Reliable active pharmaceutical ingredient supply
- Hospital and transplant-center qualification
These are operational barriers rather than strong exclusionary rights.
What FDA regulatory status applies to Myleran and busulfan?
Myleran is an FDA-approved oral busulfan product historically indicated for chronic myeloid leukemia. Intravenous busulfan products have separate regulatory histories and indications associated with transplant conditioning. The FDA’s Drugs@FDA database and approved labeling should be used to distinguish the oral product from injectable busulfan products because they differ in dosage form, exposure control, clinical use, and commercial positioning.[3]
The regulatory status does not create current market exclusivity. Busulfan is a conventional small molecule, and generic approval pathways are available where manufacturers meet FDA requirements for pharmaceutical equivalence, bioequivalence, chemistry, manufacturing, and controls.
Are there Paragraph IV challenges or Myleran patent lawsuits?
No major, commercially consequential Paragraph IV litigation is associated with the historical Myleran patent estate in the current market. The reason is economic as much as legal: the relevant core patents expired long ago, and the branded product does not have a high-value remaining exclusivity period that would justify extensive litigation.
Any litigation involving busulfan products would more likely concern:
- Manufacturing or quality disputes
- Product liability
- Supply contracts
- Regulatory compliance
- ANDA approval issues
- Labeling or formulation claims for newer products
The absence of active patent litigation supports the conclusion that Myleran is a mature genericized product rather than a protected oncology asset.
What generic-entry risks exist for Myleran?
Generic entry risk is already realized rather than prospective. The product has operated in a post-exclusivity market for years. Further entry can still reduce price and volume, particularly if additional suppliers qualify for hospital or distributor purchasing programs.
The principal risks to any remaining Myleran revenue are:
- Substitution by lower-priced oral busulfan products.
- Continued migration from oral busulfan to intravenous transplant regimens.
- Further reduction in chronic myeloid leukemia use.
- Hospital and wholesaler preference for generic supply.
- Product discontinuation or intermittent availability.
- Therapeutic substitution with targeted leukemia treatments.
The main countervailing factor is the narrow clinical need for an established oral product in selected patients. That demand can support residual sales but is unlikely to support material growth.
How does Myleran compare with competing leukemia and transplant products?
| Product or class |
Primary setting |
Competitive effect on Myleran |
| Imatinib and other TKIs |
Chronic myeloid leukemia |
Strong substitution for chronic oral busulfan |
| Intravenous busulfan |
Stem-cell transplant conditioning |
Captures busulfan demand through more controlled exposure |
| Cyclophosphamide/fludarabine combinations |
Transplant conditioning |
Compete within conditioning-regimen selection |
| Hydroxyurea |
Cytoreduction and myeloproliferative disease |
Alternative in selected hematologic settings |
| Other alkylating agents |
Hematologic oncology |
Broader therapeutic substitution |
| Generic oral busulfan |
Legacy oral use |
Direct price competition |
Myleran has the weakest position when compared with targeted leukemia therapy and the strongest residual position where clinicians specifically require oral busulfan and alternatives are unsuitable.
What is the commercial outlook for Myleran?
The outlook is stable to declining at best. A recovery in Myleran revenue would require a meaningful change in treatment practice, such as renewed use of oral busulfan in chronic myeloid leukemia or a shortage of competing products. Neither provides a durable commercial thesis.
The product may retain value in:
- Niche hematology use
- Markets with limited access to kinase inhibitors
- Regions where oral dosing is preferred
- Procurement situations favoring established brands
- Countries with fewer generic suppliers
Geographic performance can differ substantially. In lower-income or underserved markets, older cytotoxic agents may retain broader use because newer targeted therapies are less accessible. In the United States and other developed markets, clinical substitution and genericization exert stronger pressure.
Key Takeaways
- Myleran is the legacy oral formulation of busulfan.
- Its core patents and meaningful market exclusivity expired decades ago.
- Chronic myeloid leukemia treatment shifted from busulfan to BCR-ABL tyrosine kinase inhibitors.
- Transplant-related busulfan demand shifted toward intravenous products with pharmacokinetic control.
- Generic competition has eliminated meaningful brand pricing power.
- Standalone Myleran revenue is not publicly disclosed and should not be inferred from total busulfan-market estimates.
- No current, commercially significant Paragraph IV or patent-litigation threat defines the product.
- Manufacturing, supply reliability, and regulatory compliance are more important than patent rights.
- The financial trajectory is long-term decline followed by a small, durable niche rather than renewed growth.
FAQs
Is Myleran still commercially available?
Availability depends on jurisdiction and supplier status. The brand has a limited commercial role, while generic busulfan availability may vary by market and time.
Is Myleran the same as Busulfex?
Both contain busulfan, but Myleran is an oral tablet and Busulfex is an intravenous formulation. Their dosing, pharmacokinetics, approved uses, and commercial markets differ.
Does Myleran have biosimilar competition?
No. Busulfan is a chemically synthesized small molecule, so competitors use generic-drug pathways rather than biosimilar approval pathways.
Can a new busulfan formulation obtain patent protection?
Yes, if it contains novel and non-obvious technical features such as improved stability, delivery, pharmacokinetic control, or a specific treatment method. Such protection would apply to the new product rather than the legacy Myleran formulation.
Is busulfan still important in oncology?
Yes, particularly in hematopoietic stem-cell transplantation. Its continuing clinical relevance is concentrated in intravenous conditioning products, not in the historical oral Myleran market.
References
-
National Cancer Institute. (n.d.). Chronic myelogenous leukemia treatment. https://www.cancer.gov/types/leukemia/patient/cml-treatment-pdq
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
DailyMed. (n.d.). Busulfan drug labels. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/‑search.cfm?query=busulfan
